reports
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host We...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy – Webinar to be held on Tuesday, July 29, 2025, at 1:00 p.m. ET – SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it will host a webinar in collaboration with Parent Project Muscular Dystrophy (PPMD) to review the current status of Capricor’s Biologics License Application ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
More Breakouts and Risk-On Developments We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the SPX is above 5700-5785, though we believe there is a low probability that this level gets tested any time soon. Short-term supports on the SPX include the 20-day MA (currently 6233), 6200, 6100-6150, and 6028-605...
EME EMCOR GROUP
STRL STERLING CONSTRUCTION COMPANY INC.
PWR QUANTA SERVICES INC.
MTZ MASTEC INC.
GVA GRANITE CONSTRUCTION INCORPORATED
DY DYCOM INDUSTRIES INC.
BWXT BWX TECHNOLOGIES INC.
FLR FLUOR CORPORATION
MYRG MYR GROUP INC.
AGX ARGAN INC.
ROAD CONSTRUCTION PARTNERS
IESC IES HOLDINGS INC.
SNEX STONEX GROUP INC
HOOD ROBINHOOD MARKETS INC
COIN COINBASE GLOBAL INC
J JACOBS SOLUTIONS INC.
PRIM PRIME ENERGY P.E. LTD
BULL WEBULL CORPORATION
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for...
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of cardiomyopathy associated with Duchenne muscular dystrophyFDA advised Capricor to request a meeting to determine next steps toward potential approvalConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company dev...
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for...
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy FDA has indicated that an Advisory Committee meeting is not required at this timeIn-person late-cycle review meeting scheduled for mid-July Biologics License Application (BLA) remains under Priority Review with PDUFA target action date of August 31, 2025Four-year data presented at PPMD 2025 Conference demonstrate sustained cardiac function SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for r...
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-...
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow with extended treatment (PUL v2.0)Deramiocel’s long-term safety profile remains favorableResults presented at PPMD’s 2025 Annual Conference SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive fou...
Capricor Therapeutics Announces Orphan Drug Designation for Becker Mus...
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseasesCapricor remains on track for the August 31, 2025, PDUFA date for Deramiocel in Duchenne Muscular Dystrophy following successful FDA Pre-License Inspection SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-base...
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenn...
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support licensureAdvisory Committee meeting scheduled for July 30, 2025Mid-cycle meeting recently completed with no significant issues or major deficiencies; late-cycle meeting planned for mid-JulyBiologics License Application remains under priority review with PDUFA target action date of August 31, 2025 SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnolog...
Carnival Corp: 1 director
A director at Carnival Corp sold 105,010 shares at 22.841USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Capricor Therapeutics Reports First Quarter 2025 Financial Results and...
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing dee...
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Of...
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer — Dr. Binks joins Capricor in anticipation of potential approval of deramiocel in Q3 2025, bringing extensive experience in neuromuscular and rare diseases — SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translat...
Capricor Therapeutics to Present First Quarter 2025 Financial Results ...
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ET SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics ...
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting...
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy -Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of a mid-cycle review meeting with the U.S. Food and Drug Admi...
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
RDNT RADNET INC.
PBF PBF ENERGY INC. CLASS A
ORCL ORACLE CORPORATION
OMI OWENS & MINOR INC.
NEOG NEOGEN CORPORATION
MOD MODINE MANUFACTURING COMPANY
LGND LIGAND PHARMACEUTICALS INCORPORATED
KEY KEYCORP
CVGW CALAVO GROWERS INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
LPG DORIAN LPG
IRIX IRIDEX CORP.
USB US BANCORP
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
CNFR CONIFER HOLDINGS
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ALOT ASTRONOVA INC.
FBK FB FINANCIAL CORPORATION
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
FEIM FREQUENCY ELECTRONICS INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ESQ ESQUIRE FINANCIAL HOLDINGS
BCDA BIOCARDIA
MCFT MASTERCRAFT BOAT HOLDINGS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
PKE PARK AEROSPACE CORPORATION
DYNR DYNARESOURCE INC.
ALLY GMAC LLC
LPI LAREDO PETROLEUM INC.
KROS KEROS THERAPEUTICS
ASAN ASANA
PCVX VAXCYTE
NUVB NUVATION BIO INC (A)
SMMT SUMMIT THERAPEUTICS INC
BYRN BYRNA TECHNOLOGIES INC
UPST UPSTART HOLDINGS
HUMA HUMACYTE INC
BFZ BLACKROCK CALIF MUN INCOME TRUST
PEPG PEPGEN INC
PROK PROKIDNEY CORP.
GTE GRAN TIERRA ENERGY INC.
SBGI SINCLAIR INC
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
DMA DESTRA MULTI ALTERNATIVE FUND
ADVM ADVERUM BIOTECHNOLOGIES INC.
NUTX NUTEX HEALTH INC
SCND SCIENTIFIC INDUSTRIES INC
BATRK LIBERTY MEDIA CORPORATION
NBY NOVABAY PHARMACEUTICALS INC.
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ALOT ASTRONOVA INC.
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PASG PASSAGE BIO
RLAY INC.
CTGO RELAY THERAPEUTICS
TEAF CONTANGO ORE INC.
PROK ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
MIO PROKIDNEY CORP.
DMA PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
ADVM DESTRA MULTI ALTERNATIVE FUND
GF ADVERUM BIOTECHNOLOGIES INC.
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
LIND LINDBLAD EXPEDITIONS HOLDINGS
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
FEIM FREQUENCY ELECTRONICS INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
TEAF ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
GLSI GREENWICH LIFESCIENCES INC
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM EATON VANCE INSD CALIF MUN BD FD
SCND SCIENTIFIC INDUSTRIES INC
ECF ELLSWORTH FUND LTD
- Jonathan Moreland
RGP RESOURCES CONNECTION INC.
RDNT RADNET INC.
PBF PBF ENERGY INC. CLASS A
OMI OWENS & MINOR INC.
NEOG NEOGEN CORPORATION
MOD MODINE MANUFACTURING COMPANY
LGND LIGAND PHARMACEUTICALS INCORPORATED
CVGW CALAVO GROWERS INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
APA.. APA CORP.
LPG DORIAN LPG
WHF WHITEFIELD
AB ALLIANCEBERNSTEIN HOLDING L.P.
ADC AGREE REALTY CORPORATION
AMTX AEMETIS
CNFR CONIFER HOLDINGS
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
KYN KAYNE ANDERSON MLP INVESTMENT CO.
FBK FB FINANCIAL CORPORATION
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
NHF NEXPOINT CREDIT STRATEGIES FUN
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
WGO WINNEBAGO INDUSTRIES INC.
FF FIRST MINING GOLD
SONO SONOS
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
LPI LAREDO PETROLEUM INC.
KROS KEROS THERAPEUTICS
ASAN ASANA
PCVX VAXCYTE
NUVB NUVATION BIO INC (A)
UAN CVR PARTNERS LP
SMMT SUMMIT THERAPEUTICS INC
FTCI FTC SOLAR
PFBX INC.
UPST PEOPLES FINANCIAL CORP. (MISSISSIPPI)
HUMA UPSTART HOLDINGS
BFZ HUMACYTE INC
PEPG BLACKROCK CALIF MUN INCOME TRUST
EWTX PEPGEN INC
GLSI EDGEWISE THERAPEUTICS INC
JMSB GREENWICH LIFESCIENCES INC
MEGI JOHN MARSHALL BANCORP INC
NMTC MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
VANI NEUROONE MEDICAL TECHNOLOGIES CORP
PROK VIVANI MEDICAL INC
GTE PROKIDNEY CORP.
SBGI GRAN TIERRA ENERGY INC.
MIO SINCLAIR INC
NUTX PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
BATRK NUTEX HEALTH INC
ECF LIBERTY MEDIA CORPORATION
NBY ELLSWORTH FUND LTD
NOVABAY PHARMACEUTICALS INC.
- Jonathan Moreland
FLWS 1-800-FLOWERS.COM CL A
NHF NEXPOINT CREDIT STRATEGIES FUN
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
HQL TEKLA LIFE SCIENCES INVESTORS
ASAN ASANA
HUMA HUMACYTE INC
BFZ BLACKROCK CALIF MUN INCOME TRUST
TEAF ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
JMSB JOHN MARSHALL BANCORP INC
PROK PROKIDNEY CORP.
GTE GRAN TIERRA ENERGY INC.
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
NUTX NUTEX HEALTH INC
EVM EATON VANCE INSD CALIF MUN BD FD
BATRK LIBERTY MEDIA CORPORATION
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
MUSA MURPHY USA INC.
MOS MOSAIC COMPANY
HNRG HALLADOR ENERGY CO.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GT GOODYEAR TIRE & RUBBER COMPANY
FAST FASTENAL COMPANY
BGS B&G FOODS INC.
CNR. CANADIAN NATIONAL RAILWAY COMPANY
AGX ARGAN INC.
LEU CENTRUS ENERGY CORPORATION
GRPN GROUPON INC.
IPI INTREPID POTASH
SBTX SILVERBACK THERAPEUTICS
SDGR SCHRODINGER
RGC REGENCELL BIOSCIENCE HLDGS LTD
PPTA PERPETUA RESOURCES CORP
MPTI M TRON INDUSTRIES INC
ASPI ASP ISOTOPES INC
ANG ANGLOGOLD ASHANTI LIMITED
AZ A2Z CUST2MATE SOLUTIONS CORP
USAU US GOLD CORP
SLNO SOLENO THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
- Jonathan Moreland
TDOC TELADOC HEALTH INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
RGP RESOURCES CONNECTION INC.
RDNT RADNET INC.
OPK OPKO HEALTH INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
AMTX AEMETIS
CNFR CONIFER HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
CMPX COMPASS THERAPEUTICS
NUVB INC.
HUMA NUVATION BIO INC (A)
BUKS HUMACYTE INC
GLSI BUTLER NATIONAL CORP
VANI GREENWICH LIFESCIENCES INC
GTE VIVANI MEDICAL INC
EVM GRAN TIERRA ENERGY INC.
EATON VANCE INSD CALIF MUN BD FD
Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Car...
Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company will present at the 2025 Piper Sandler Virtual Cardio Day taking place on April 2, 2025. Capricor will take part in a fireside chat to discuss the company’s latest advancements on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.